Abstract
Omega-3 fatty acid (O-3FA) supplementation has garnered interest since cardioprotective properties of dietary fish consumption were observed. In the general population, O-3FA supplementation has not improved cardiovascular outcomes. However, icosapent ethyl, a high-dose, purified form of eicosapentaenoic acid, has demonstrated additive cardioprotection to statins in high-risk patients with elevated triglycerides.